Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of imlifidase-treated kidney transplant recipients with a concurrent reference transplant cohort
NL-OMON59439Phase 3Active, not recruiting
- Sponsor
- Hansa Biopharma
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of efgartigimod alfa in kidney failure and Allosensitization (2 cohorts), sponsored by Hansa Biopharma. Started Feb 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
kidney failureAllosensitization
Beyond the preview
Go deeper on NL-OMON59439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59439.